Nuvation Bio heads into its May 8 earnings report with short sellers making a clear statement — and options traders ignoring them entirely.
Short interest has become the dominant feature of the positioning picture. At roughly 22% of the free float, it has climbed for four consecutive weeks, rising about 6% over the past week alone and nearly 8.5% over the past month. The ORTEX short score — a composite of short-side signals — has pushed to 78.7, up sharply from 76.2 just two weeks ago and placing NUVB in a highly elevated short-score percentile (ranked 4th across its universe). Availability in the lending market has tightened to 40%, meaning less than one share is available for every 2.5 already borrowed — firmly in the tight range. Borrow costs, however, remain benign at around 0.45%, suggesting the short build is deliberate accumulation rather than a panic squeeze. The stock has shed 3.3% over the past week to $4.41.
Options investors are telling a different story. The put/call ratio is running below its 20-day average at 0.42 — slightly on the call-heavy side rather than the defensive positioning one might expect given the short accumulation. The reading is roughly half a standard deviation below its recent mean, and is nowhere near the defensive extremes the 52-week high of 1.23 has seen. The contrast is notable: short sellers are pressing, while options traders have not shifted toward protection.
Insiders have been consistent sellers. A Chief Level Officer and the Chief Medical Officer both sold shares in mid-April, just weeks before the print — at $5.01 and $5.02 respectively. Those sales follow a pattern of executive disposals stretching back through November 2025, when the CSO and CMO each sold material positions at prices between $7 and $8. The stock has traded well below those levels since. The company's largest single shareholder, founder David Hung, holds 17.3% of shares with no reported change.
Analyst opinion is split but leans bullish. Wedbush has held its $11 Outperform rating steady across multiple reiterations in 2026. RBC Capital raised its target to $13 in early March, while UBS took the other side — lowering its target from $10 to $7 and holding at Neutral. The bull case centres on taletrectinib's commercial momentum in ROS1+ NSCLC and the Eisai licensing deal, with expectations of roughly $21 million in Q1 revenue. The bear case flags dilution risk and competitive pressure. The mean analyst target of $12.33 implies substantial upside from the current price of $4.41, though that gap also reflects how far the stock has fallen from the levels at which most targets were set.
The May 8 print is therefore a test of whether early commercial uptake for taletrectinib can justify the bull case — and whether shorts, who have been quietly building a position all month, have correctly anticipated a miss.
See the live data behind this article on ORTEX.
Open NUVB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
